Post-COVID-19 Chest Pain Linked to Coronary Microvascular Dysfunction Caused by SARS-CoV-2
Nikhil Prasad Fact checked by:Thailand Medical News Team Apr 07, 2026 1 hour, 50 minutes ago
Medical News: A growing body of clinical evidence is shedding light on a lesser-known cardiovascular complication emerging after COVID-19 infection. A recent case series has revealed that some patients experiencing persistent chest pain and shortness of breath may be suffering from coronary microvascular dysfunction (CMD), even when standard cardiac tests show no abnormalities.
Persistent chest pain after COVID-19 may be due to impaired blood flow in the heart’s smallest vessels despite normal
standard tests
New Insights into Post-COVID-19 Heart Symptoms
Researchers from the Department of Medicine and the Division of Cardiovascular Medicine at the University of Florida, Gainesville, Florida, USA, investigated three patients who developed ongoing cardiovascular symptoms following SARS-CoV-2 infection. Despite undergoing routine cardiac evaluations, none of the patients showed evidence of blocked major coronary arteries. However, advanced testing revealed significantly impaired coronary flow reserve, confirming the presence of CMD.
This finding is particularly important because it highlights a condition that may not be detected through conventional diagnostic approaches, potentially leading to delays in appropriate care.
Understanding Coronary Microvascular Dysfunction
CMD affects the smallest blood vessels within the heart, impairing their ability to regulate blood flow efficiently. Unlike traditional coronary artery disease, which involves blockages in larger arteries, CMD occurs at a microscopic level and does not appear on standard imaging tests.
In all three cases, coronary flow reserve values were below 2.0, indicating reduced blood flow capacity despite normal-appearing epicardial arteries. This suggests that patients may experience genuine cardiac symptoms even when initial test results appear reassuring.
Patient Cases Highlight Diagnostic Challenges
The clinical cases illustrate how CMD can remain undiagnosed for extended periods. One patient, a former competitive athlete, experienced persistent symptoms for more than a year before receiving a diagnosis. Another patient reported symptoms lasting nearly six years, while a third was diagnosed after approximately ten months.
Common symptoms included chest pain, breathlessness, fatigue, and reduced tolerance for physical activity. In each case, standard noninvasive tests such as stress electrocardiograms, echocardiography, and heart rhythm monitoring did not identify the underlying problem.
As observed in the study, patients typically followed a pattern of persistent symptoms after COVID-19, normal initial testing, and eventual diagnosis through specialized coronary flow assessment. This sequence underscores the limitations of current diagnostic pathways.
Potential Mechanisms Linking COVID-19 and CMD
The study adds to growing evidence that COVID-19 may affect the cardiovascular system beyond acute infection. Researchers suggest that inflammation of the vascular lining, microvascular injury, and abnormal blood vess
el responses may contribute to impaired coronary circulation.
These changes can reduce the ability of small vessels to deliver adequate oxygen to the heart muscle, particularly during physical exertion, leading to symptoms that resemble angina.
An Emerging Concern
This
Medical News report emphasizes the importance of recognizing CMD as a potential cause of persistent cardiovascular symptoms in patients recovering from COVID-19. Because routine diagnostic tools may not detect the condition, clinicians may need to consider additional testing when symptoms persist without clear explanation.
Earlier use of coronary reactivity testing or advanced imaging modalities such as positron emission tomography and cardiac magnetic resonance imaging may help identify affected individuals more efficiently.
Treatment and Clinical Outcomes
All patients in the case series showed improvement following targeted treatment strategies. These included medications such as calcium-channel blockers, beta-blockers, nitrates, and structured exercise programs tailored to individual tolerance levels.
While CMD can be a chronic condition, appropriate management appears to significantly reduce symptom burden and improve daily functioning. The findings suggest that timely diagnosis is key to achieving better clinical outcomes.
Conclusions
This case series highlights the need for increased clinical awareness of coronary microvascular dysfunction in patients with persistent symptoms following COVID-19 infection. The condition may explain ongoing chest pain and exercise intolerance in individuals with otherwise normal cardiac evaluations. Given the limitations of standard diagnostic tools, clinicians should consider advanced testing in patients with unexplained symptoms. Early identification and targeted therapy can improve quality of life and reduce the burden of long-term cardiovascular complications. As understanding of post-COVID conditions continues to evolve, CMD is likely to become an important focus in both research and clinical practice.
The study findings were published in the peer reviewed journal: JACC Case Reports.
https://www.jacc.org/doi/10.1016/j.jaccas.2026.107508
For the latest COVID-19 news, keep on logging to Thailand
Medical News.
Read Also:
https://www.thailandmedical.news/articles/coronavirus
https://www.thailandmedical.news/articles/long-covid
https://www.thailandmedical.news/articles/cardiology
Share
Tweet
Share
